Search
Filter Results
Displaying 1–10 of 101 for “pharmaceuticals”
-
Jun 15, 2022
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
Bronze Partner - Janssen Pharmaceutical Companies
Bronze Partner - Janssen Pharmaceutical Companies
-
Jun 20, 2022
The newly approved drug reduces the pathologic hunger associated with BBS
-
Nov 9, 2020
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
The Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
Jul 17, 2020
A Phase 3 trial for the treatment is planned
-
May 13, 2020
jCyte Enters into Licensing Agreement with Santen Pharmaceutical for Cell Therapy
Emerging treatment designed to preserve vision for people with RP and related conditions
-
Dec 6, 2023
Recording Available: Foundation Insights Forum – November 30, 2023
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on November 30, 2023.
-
May 20, 2022
Foundation Insights Forum – May 13, 2022
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on May 13, 2022.
-
Feb 3, 2021
Foundation Insights Forum – January 29, 2021
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on January 29, 2021.
-
Nov 10, 2020
Foundation Insights Forum – October 29, 2020
The Foundation Fighting Blindness is pleased to provide an audio recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on October 29, 2020.